Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Prasinezumab

            Therapeutic Area: Neurology Product Name: PRX002

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

            Deal Size: $60.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration May 10, 2021

            Details:

            Company has earned a $60 million milestone from its worldwide collaboration with Roche based on the first patient dosed in the Phase 2b PADOVA study of prasinezumab in patients with early Parkinson's disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ropivacaine Hydrochloride

            Therapeutic Area: Neurology Product Name: PRF-110

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 18, 2021

            Details:

            PRF-110 is based on the local anesthetic ropivacaine, targeting post-operative pain relief market. PRF-110 is an oil-based, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia.